TraumaStim: Repetitive Transcranial Magnetic Stimulation Plus Reactivation Therapy Efficacy on PTSD Symptom Severity in Resistant PTSD
Study Details
Study Description
Brief Summary
A French multicenter randomized and double blinded shamed controlled study recruiting patients who present resistant PTSD. The aim of this trial is to assess the efficacy of cerebral modulation by rTMS with simultaneous reactivation of traumatic memory on the PTSD symptoms at M1.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Detailed Description : PTSD is considered as one of the top 10 public health concerns. Most patients with PTSD receive pharmacologic treatment and traumatic reactivation therapy. However, to date, the optimal treatment alternatives for non-responders PTSD patients are unknown.
Functionally, the metabolic activity of the prefrontal-amygdala cortex circuit in PTSD is significantly altered. Repetitive Transcranial Magnetic Stimulation (rTMS) provides focused, non-invasive stimulation of cortical areas of the central nervous system and could correct cortical defective activation of the prefrontal cortex seen in PTSD Patient (FDA has already approved rTMS for depression and acoustic-verbal hallucinations treatment).
Pairing rTMS with cues relevant to the trauma may be a novel approach to treat PTSD patient.
The study will enroll 102 subjects with resistant PTSD. After screening and inclusion phase, the treatment phase with 12 sessions of rTMS and simultaneous reactivation of traumatic memory or sham rTMS and simultaneous reactivation of traumatic memory will be performed (3 to 4 weeks). Antidepressant treatment will be maintained. The follow up phase consist of 3 visits at M1, M3 and M6 to follow the evolution of the PTSD symptoms.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: rTMS with simultaneous reactivation of traumatic memory in resistant PTSD rTMS with simultaneous reactivation of traumatic memory in resistant PTSD during 12 sessions (3 to 4 weeks) |
Procedure: Repetitive Transcranial Magnetic Stimulation (rTMS)
rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.
A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions.
|
| Placebo Comparator: sham rTMS and simultaneous reactivation of traumatic memory in resistant PTSD sham rTMS and simultaneous reactivation of traumatic memory in resistant PTSD during 12 sessions (3 to 4 weeks) |
Procedure: Placebo
sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.
A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions.
|
Outcome Measures
Primary Outcome Measures
- PTSD severity score measured at M1 after 12 sessions of rTMS or sham rTMS and simultaneous reactivation of traumatic memory [Month 1 after 12 sessions of rTMS]
CAPS-5 total severity score at M1 post treatment will be compared between groups (cerebral modulation by rTMS with simultaneous reactivation of traumatic memory VS sham rTMS with simultaneous reactivation of traumatic memory)
Secondary Outcome Measures
- PTSD severity scores at M3 and M6 measured with CAPS-5 [At inclusion (v1), Month 3 and Month 6 post treatment]
The different dimensions of PTSD (assess by CAPS-5): Severity, repetition, avoidance, neurovegetative activation at M3 and M6 post treatment
- The severity of PTSD assessed by PCL-5 at each visit. [at once a during TMS sessions, Month1, Month 3 and Month 6 post treatment.]
PTSD severity score measured with the PTSD Checklist (PCL-S self-questionnaire) at once a during TMS sessions, M1, M3 and M6 post treatment
- Dissociative symptoms severity scores (1) [at inclusion (V1), up to 4 weeks (V13) (end of treatment), Month 1, Month 3, Month 6 post treatment]
Dissociative symptoms severity score measured with the Clinician Administered Dissociative States Scale (CADSS)
- Dissociative symptoms severity scores (2) [at inclusion (V1), up to 4 weeks (V13) (end of treatment), Month 1, Month 3, Month 6 post treatment]
The Multidimensional Assessment of Interoceptive Awareness (MAIA)
- Dissociative symptoms severity scores (3) [at inclusion (V1), up to 4 weeks (V13) (end of treatment), Month 1, Month 3, Month 6 post treatment]
The Dissociative Experiences Scale (DES)
- The severity scores of the dimensions of anxiety at V13 (end of treatment), M1, M3, M6 post treatment. [Up to 4 weeks (V13) (end of treatment), Month 1, Month 3, Month 6 post treatment.]
The severity scores of the dimensions of anxiety measured with HAM-A at V13 (end of treatment), M1, M3 and M6.
- Symptoms of depression at V13 (end of treatment), M1, M3, M6 post treatment. [at V13 (end of treatment), Month 1, Month 3, Month 6 post treatment.]
The severity scores of the dimensions of depression measured with HAM-D at V13 (end of treatment), M1, M3 and M6.
- Evolution of social cognition at M3 post treatment. [at Month 3 post treatment]
Evolution of social cognition at M3 post treatment by a neuropsychologist
- Quality of life [post treatment and Month 6]
Quality of life evolution post treatment and M6 assessed by WHOQOL EuroQol Health Measure
- Quality of life [post treatment and Month 6]
Quality of life evolution post treatment and M6 assessed by EQ-5D-5L
- Proportion of adverse events during the active treatment phase and during the follow-up [through study completion, up to 6 months]
Number and description of adverse events during the active treatment phase and during the follow-up
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients aged between 18 and 65 years.
-
Presenting a PTSD according to DSM-5 criteria
-
Patient with persistent symptoms (PCL-5>40) after a 6 weeks treatment with labelled antidepressant for PTSD (paroxetine or sertraline)
-
Patient with health insurance (AME excepted)
-
Signed written inform consent
Exclusion Criteria :
-
Contraindication for rTMS:
-
History of epilepsy or seizure
-
Cochlear implants
-
Cardiac pacemaker or intracardiac lines, or metal in the body
-
Patient has already had a rTMS session and/or Electroconvulsive therapy (ECT) and/or Transcranial direct current stimulation (tDCS)
-
Ongoing PTSD-oriented cognitive-behavioral therapy
-
Lifetime psychotic or bipolar disorder or antisocial personality or borderline personality
-
Brain injury defined by medical report (including cortical and subcortical atrophy, dementia, stroke, transient ischemic attack and head trauma)
-
Current substance dependence (including alcohol, excluding tobacco);
-
Acute suicidal ideation
-
No adequate mastering of the French language or no ability to consent
-
Pregnancy (confirmed by a urine test beta-HCG) or breast feeding or absence of birth control
-
Patient under legal protection measure and or deprived of freedom
-
Participation in any other interventional study or in the exclusion period any other interventional study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Saint Antoine Hospital, Psychiatry department, Assistance Publique- Hôpitaux de Paris | Paris | France | 75012 |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
Investigators
- Principal Investigator: Florian FERRERI, MD, ph, Assistance Publique - Hôpitaux de Paris
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APHP200044
- 2021-A02532-39-B